Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples